[en] Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic bone diseases characterised by excessive bone resorption, such as osteoporosis. Most randomised studies in which salcatonin and oral calcium were administered for 1 to 5 years to recently postmenopausal women for the prevention of osteoporosis have shown that bone mineral density or bone content of the lumbar spine increased significantly, compared with a reduction among women receiving calcium only. Prospective studies have shown that salcatonin is effective in the treatment of established osteoporosis, reducing significantly the relative risk of new vertebral fractures. The benefits of salcatonin nasal spray therapy were observed in the majority of women studied, and it has been shown to be an effective alternative for osteoporotic women more than 5 years postmenopausal who refuse estrogens, or for whom estrogens are contraindicated. Finally, in established osteoporosis, nasal calcitonin possesses a potent analgesic effect. The well-demonstrated effects of nasal calcitonin permit it to be considered a well tolerated and efficient approach for prevention and treatment of postmenopausal osteoporosis.
Disciplines :
General & internal medicine
Author, co-author :
Halkin, V
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Efficacy and Tolerability of Calcitonin in the Prevention and Treatment of Osteoporosis
Publication date :
October 1998
Journal title :
BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Wolffe HJ. Calcitonin; perspective in current concepts. J Endocrinol Invest 1982; 5: 523-30
MacIntyre I, Craig R. Molecular evolution of the calcitonins. In: Fink G, Whalley, J, editors. Neuropeptides: basic and clinical aspects. London: Churchill Livingstone, 1982: 255-8
Gaines Das RE, Zanelli JM. The international reference preparation of calcitonin, human, for bioassay: assessment of material and definition of the international unit. Acta Endocrinol 1980; 93: 37-42
Zimolo Z, Wesolowski G, Rodan AG. Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 1995; 96: 2277-83
Plosker GL, McTavish D. Intranasal salcatonin: a review of its pharmacological properties and in the management of postmenopausal osteoporosis. Drugs Aging 1996; 8: 378-400
Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24: 565-9
Ribot C, Tremollieres F, Pouilles JM, et al. Long-term effect of nasal calcitonin on vertebral and femoral bone mass in early menopause : results of a controlled prospective 3-year study. J Bone Miner Res 1992; 7 Suppl. 1: 196
Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus calcitonin given into different regimens in postmenopausal osteoporosis. Curr Ther Res 1985; 38: 455-64
Overgaard K, Hansen MA, Christiansen C. Effect of intranasal calcitonin on bone mass and bone turnover in early postmenopausal women: a dose-response study. J Bone Miner Res 1992; 7 Suppl. 1: 140
Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 4 Suppl. 6: 629-632
Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int 1991; 1: 7-14
McIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; I: 900-2
Geusens P, Boonen S, Nijs J. Effect of salmon calcitonin on femoral bone quality in adult ovariectomized ewes. Calcif Tissue Int 1996; 59: 315-20
Lyritis G, Magiasis B, Tsakalakos N. Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. Calcif Tissue Int 1995; 56: 38-41
Ellerington MC, Hillard TC, Whitecroft SIJ. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59: 6-11
Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98: 452-8
Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997; 36: 255-9
Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993; 328: 1747-52
Kotaniemi A, Piirainen H, Paimela L, et al. Intranasal salmon calcitonin (sCT) prevents bone loss in active rheumatoid arthritis (RA) with low dose glucocorticoids [abstract]. Arthritis Rheum 1994; 37 Suppl. 9: 288
Canniggia A, Gennari C, Bencini M, et al. Calcium metabolism and 47-calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis. Clin Sci 1970; 38: 397-407
Milhaud G, Talbot JN, Coutris G. Calcitonin treatment of postmenopausal osteoporosis, evaluation of efficacy by principal component analysis. Biomedicine 1975; 23: 223-32
Reginster JY. Calcitonin for prevention and treatment of osteoporosis. Am J Med 1993; 95 Suppl. 1: 44-7
Rico H, Revilla M, Hernandez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56: 181-5
Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995; 17: 680-5
Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35-9
Stock JL, Avioli LV, Baylink DJ. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: three-year interim results of the PROOF study [abstract no. 187]. J Bone Miner Res 1997; 12 Suppl. 1: S149
Reginster JY, Gaspard S, Deroisy R. Prevention of osteoporosis with nasa salmon calcitonin: effect of anti-salmon calcitonin antibody formation. Osteoporos Int 1993; 3: 261-4
Takahashi S, Goldring S, Katz M, et al. Down-regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 1995; 95: 167-71
Reginster JY, Franchimont P. Side-effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985; 3: 155-7
Foti R, Martorana U, Broggini M. Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 1995; 56 Suppl. 4: 429-35
Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556-61
Thamsborg G, Storm TL, Sykulski R, et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991; 41: 302-7
Nagant De Deuxchaisnes C, Devogelaer JP, Huaux JP, et al. New modes of administration of salmon calcitonin in Paget's disease. Clin Orthop Relat Res 1987; 217: 56-71
Overgaard K, Aynusdei D, Hansen MA, et al. Dose-response bioactivity of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72: 344-9
Reginster JY, Denis D, Albert A, et al. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (im) or placebo injection in normal subjects. Bone Miner 1987; 2: 133-40
Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind study. Calcif Tissue Int 1986; 38: 3-8
Guidobono F, Netti C, Villani P, et al. Antinociceptive activity of eel calcitonin, injected into the inflamed paw in rats. Neuropharmacology 1991; 30: 1275-8
Ljunghall S, Gardsell P, Johnell O, et al. Synthetic human calcitonin in postmenopausal osteoporosis a placebo-controlled, double-blind study. Calcif Tissue Int 1991; 49: 17-9
Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double blind placebo-controlled clinical study. Calcif Tissue Int 1991; 49: 369-72
Pun KK, Shan LWL. Analgesic effect of salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989; 11: 205-9
